There are 2867 resources available
445TiP - VIVA trial: A randomized phase II study of adjuvant regorafenib plus durvalumab in stage IV colorectal cancer patients achieving the no evidence of disease state
Presenter: Alessandro Pastorino
Session: Poster session 08
446TiP - Randomized phase III study of bi-weekly trifluridine/tipiracil (FTD/TPI) plus bevacizumab (BEV) vs. FTD/TPI for chemorefractory metastatic colorectal cancer (mCRC): ROBiTS/JCOG2014
Presenter: Kentaro Yamazaki
Session: Poster session 08
447TiP - Neoadjuvant long-course chemoradiation plus tislelizumab (anti-PD1) for MMR-status-unscreened locally advanced rectal cancer: Study protocol for a phase II, 3-arm, randomized trial
Presenter: Yingchi Yang
Session: Poster session 08
448TiP - A multicenter single arm phase II trial evaluating the safety and the efficacy of panitumumab and irinotecan for patients with NeoRAS wild-type metastatic colorectal cancer (C-PROWESS trial)
Presenter: Hiroki Osumi
Session: Poster session 08
449TiP - Evaluation of regorafenib treatment PERSOnalization based on therapeutic drug monitoring in patients with metastatic colorectal cancer (mCRC): RePERSO study
Presenter: Camille Tron
Session: Poster session 08
497P - Prognostic impact of venous and lymphatic invasion of pancreatic neuroendocrine neoplasm in patients undergoing resection
Presenter: Junichi Arita
Session: Poster session 08
498P - Generation of CAR T cells expressing a scFV targeting the hTSHR in thyroid cancer
Presenter: Murtaza Ali
Session: Poster session 08
499TiP - Surufatinib combined with sintilimab and IBI310 in the treatment of high-grade advanced-neuroendocrine neoplasm: A single arm, open-label, multicenter study
Presenter: Ming Lu
Session: Poster session 08
530P - PRIMA/ENGOT-OV26/GOG-3012 study: Updated long-term PFS and safety
Presenter: Antonio Jose Gonzalez Martin
Session: Poster session 08
531P - Maintenance olaparib monotherapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) without a germline BRCA1/BRCA2 mutation (non-gBRCAm): Final overall survival (OS) results from the OPINION trial
Presenter: Andres Maria Poveda Velasco
Session: Poster session 08